Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 32Lymphoid 28Myeloid 6Plasma cell 3Genitourinary 3Gastrointestinal 2Classical hematology 2Thoracic 1Other solid neoplasm 1Dermatologic 1

Conditions

Pancreatic Neoplasms 1Mesothelioma 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 1152Cisplatin 876Pemetrexed 834pembrolizumab 608Paclitaxel 598Docetaxel 535Gemcitabine 424Radiotherapy 377Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 295durvalumab 254Drug Therapy 233osimertinib 218atezolizumab 208Radiosurgery 190Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 124Magnetic Resonance Spectroscopy 121Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pentostatin × Thoracic × Clear all
NCT01362790 2019-06-06

SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
55 enrolled 22 charts
GastrointestinalOther solid neoplasmThoracic

Adenocarcinoma of Lung, Mesothelioma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡